ADC Therapeutics (ADC Therapeutics) Loans Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Loans Receivable?

ADC Therapeutics's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

ADC Therapeutics Loans Receivable Historical Data

The historical data trend for ADC Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Loans Receivable Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Loans Receivable

Get a 7-Day Free Trial

ADC Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

ADC Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

ADC Therapeutics Loans Receivable Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.